

ITL Limited

Interim result points to turnaround



25 February 2005

www.macquarie.com.au

At A Glance

ITD AU relative to volatility index Outperform ex 100 very high

stock price as of 24 Feb 05 \$0.14
valuation \$0.21

GICS sector healthcare
market cap \$14m
number of shares on issue 99.6m

Investment fundamentals

Y/E 30 June	04a	05e	06e
revenue (\$m)	21.7	23.2	25.1
reported profit (\$m)	-2.0	-0.9	1.3

adjusted profit (\$m)	-1.4	-0.2	1.9
earnings per share (adjusted)	-1.4c	-0.2c	1.9c
price to earnings ratio	n/a	n/a	7.7x

dividend per share	nil	nil	nil
yield	n/a	n/a	n/a
franking	n/a	n/a	n/a

What does ITL Limited do?

ITL is an Australian based medical safety product innovator and manufacturer formed in 1994. To this point it has targeted the blood collection market where it has secured a dominant global position for specific products. ITL will continue to develop a new generation of medical safety devices to provide earnings growth.

ITL has also expanded into the design and manufacture of medical procedure kits that broaden its income base.

Event

- ITL has released its interim result, a reported loss of \$1.6m, but with clear signs of a turnaround within the business.
- Revenues for the half were \$11m, while the company incurred one off charges close to \$2m from restructuring the company to better position it for a return to profitability.
- The outlook for the current half is very encouraging, with the expectation of further revenue growth and a profit after tax of \$0.8m.

Impact

Result clears the deck – CEO Bill Mobbs has used this result to position ITL for growth and a return to profits. He and the Board have taken the opportunity to remove significant staff costs and write-off capitalised R&D following the failure of the Clinical Choice product range with the Procedure Kits division.

Healthy current half outlook welcome – The Company anticipates a solid turnaround in the current half with expectations “to post half-year revenue of \$12 million and a profit after tax of \$800,000, with EBITDA [Earnings before interest, tax, depreciation & amortisation] of \$1.75 million”. This is welcome news for shareholders.

Underlying operations travelling well – Both the Innovative Products and Procedure Kits divisions look to be in a lot better state. Existing contracts are being renewed while new contracts are being written. With a focus on profitability for the year ahead, rather than just growing revenues, we should expect to see an improvement in profit margins.

Valuation, target & catalyst

Valuation: 21c

Catalyst: Delivery on earnings expectations

Action & recommendation

An investment in ITL is not without risks given its history since listing. However, with the efforts of significantly reducing unnecessary costs within the business, ITL is now positioned to grow earnings. Looking one year out, we see a meaningful recovery in profitability.

Notwithstanding a reduction of our valuation to 21 cents (reflecting lower cash balance and reduced earnings from the first half), the stock looks cheap. The current share price of 14 cents compares with our valuation and a net tangible asset value of 13.5 cents per share.

Accordingly, we are upgrading our recommendation to Outperform.

Operational review results in significant one-off charges

The result included \$1.985m of one off charges. This follows a decision by the company to act on the underperformance of the company with Joint Managing Directors and the failure of the Clinical Choice range within the Procedure Kits division.

The charges were made up of:

- \$891,000 of separation payments;
- \$964,000 write-off of capitalised Research & Development associated with the Clinical Choice product range; and
- \$130,000 of US patent litigation expenses, representing the tail end of the Platypus patent infringement litigation.

We believe this effort places ITL in a far better position to grow profits with excessive costs removed and the ability to concentrate on product ranges that will grow revenues.

Innovative products

The Innovative Products division staged a healthy turnaround in the first half compared to the same period in the previous year. Revenues were up 30% to \$3.9m, while the profit of \$0.65m compares with a loss of \$0.5m in the same period in the previous year.

The Samplok Sampling Kit, which received US Food & Drug Administration approval early in 2004, is now a very strong product for ITL. Meanwhile, volumes for the Donor Care product are stable. It was with this product where ITL struck problems in the previous corresponding period, when US blood collection volumes were down significantly.

We expect to see a further improvement in profitability in this division as we understand ITL air freighted a significant amount of product from its Malaysian manufacturing plant to US customers in order to fill demand during the last half. This practice has effectively ceased with the supply chain working more effectively.

Procedure Kits

This division wrote revenues of \$7.0m but reported a loss of \$1.15m. This is not directly comparable with the same period in the previous year because that only contained two months of operating from the Surgicare business, which accounts for the bulk of the business generation. The first half revenue compares with full year revenue for 2004 of \$12.3m from Surgicare.

Included in this division's loss for the half were substantial one-off charges for the write-off of capitalised R&D associated with the failed Clinical Choice products, as well as staff redundancies. We note that the original vendors of Surgicare to ITL, Peter & Nola Gray, left the company during the half. In a further effort to reduce costs, ITL also closed its NZ sales office and cut its sales force in Malaysia.

The outlook for the procedure kits market is still positive. There is still a large amount of the market that is unconverted to procedure kits - we believe only 10-15% of procedures utilise procedure kits. This compares with a penetration rate for kits in the US is in the order of 60-65% of procedures.

Current valuation range sits between \$0.19 – 0.22

We have based our valuation on a Capitalisation of earnings method. We have pitched the range below that of the average Emerging Leaders Enterprise value / Earnings (before interest, tax, depreciation & amortisation) multiple for 2005 given the difficulty ITL has had in reaching expectations.

Our valuation range for ITL now sits between \$0.19 – 0.22 (previously \$0.34). This reflects the lower cash balance (after debt) at 31 December 2004 and Earnings (before interest, tax, depreciation & amortisation) forecasts for the current year, excluding one-off charges incurred during the December half.

Capitalisation of earnings

	EV/EBITDA multiple		FY05E EBITDA	Valuation	
	Low	High		Low (\$m)	High (\$m)
Emerging leaders (ex resources)		9.4x			
ITL Ltd	7.4x	8.4x	\$2.3m	17.0	19.3
<u>Add</u> net cash (after debt)				2.2	2.2
Equity value				19.2	21.5
Value per share				\$0.19	\$0.22

EV – Enterprise value. A measure of what the market believes a company's ongoing operations are worth. Enterprise value is equal to (company's market capitalisation + debt + preferred stock - cash and cash equivalents). EBITDA - Earnings before Interest, Tax, Depreciation and Amortisation.

Source: MFS Research, MRE, ITL Ltd

Recommendation Definition

'Outperform' - return > 5% in excess of benchmark return

'Neutral' - return within 5% of benchmark return

'Underperform' - return > 5% below benchmark return

term: 12 months

Volatility Index Definition

This factor has been calculated from the volatility of historic price movements.

Very High - Highest Risk. Stock should be expected to move up or down 60 - 100% in a year. Investors should be aware this stock is highly speculative.

High - Stock should be expected to move up or down at least 40 - 60% in a year. Investors should be aware this stock could be speculative.

Medium - Stock should be expected to move up or down at least 30 - 40% in a year.

Low/Medium - Stock should be expected to move up or down at least 25 - 30% in a year.

Low - Stock should be expected to move up or down at least 15 - 25% in a year.

MACQUARIE FINANCIAL SERVICES' CONTACT DETAILS

ADELAIDE

1st Floor, West Wing
50 Grenfell Street
Adelaide SA 5000
Tel: 08 8203 0200
Fax: 08 8212 4829

AUCKLAND

Level 14, Phillips Fox Tower
National Bank Centre
209 Queen St
Auckland, New Zealand
Tel: 09 357 6931
Fax: 09 363 1448

BRISBANE

Level 2 Waterfront Place
1 Eagle Street
Brisbane QLD 4000
Tel: 07 3233 5888
Fax: 07 3233 5999

CHRISTCHURCH

Level 17, Forsyth Barr House
764 Colombo Street
Christchurch, New Zealand
Tel: 03 366 8851
Fax: 03 366 8852

GOLD COAST

12 Short Street
Southport QLD 4215
Tel: 07 5532 8955
Fax: 07 5532 8731

MELBOURNE

Level 23, 101 Collins St
Melbourne VIC 3000
Tel: 03 9635 8383
Fax: 03 9635 8326

PERTH

Level 28, Allendale Square
77 St George's Terrace
Perth WA 6000
Tel: 08 9224 0888
Fax: 08 9224 0895

SUNSHINE COAST

69 Mary Street
Noosaville QLD 4566
Tel: 07 5474 1608
Fax: 07 5474 2359

SYDNEY

Level 19, 20 Bond Street
Sydney NSW 2000
Tel: 02 8232 6767
Fax: 02 8232 4055

WELLINGTON

Ground Floor, Lombard House
95 Customhouse Quay
Wellington, New Zealand
Tel: 04 462 4999
Fax: 04 462 4900

© Macquarie Group Notes: This research has been prepared for the use of the clients of Macquarie Bank Ltd and its wholly-owned subsidiaries (the "Macquarie Group") and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way.

This research has been issued and distributed in Australia, by Macquarie Equities Limited ABN 41 002 574 923 ("MEL"), trading as Macquarie Financial Services, is a holder of a Australian Financial Services Licence No. 237504 and is a Participant of the Australian Stock Exchange Group. MEL is not an authorised deposit-taking institution for the purposes of the Banking Act (Cth) 1959, and MEL's obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542. Macquarie Bank Limited does not guarantee or otherwise provide assurance in respect of the obligations of MEL.

This research is based on information obtained from sources believed to be reliable and MEL has made every effort to ensure the information in this report is accurate, but we do not make any representation or warranty that it is accurate, reliable, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice and accurately reflect the analyst(s)' personal views at the time of writing. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. The Macquarie Group or its associates, including MEL, officers or employees may have interests in the financial products or a relationship with the issuer of the financial products referred to in this report by acting in various roles including as investment banker, underwriter or dealer, holder of principal positions, broker, lender, director or adviser. Further, they may act as market maker or buy or sell those securities as principal or agent, and as such may effect transactions which are not consistent with the recommendations (if any) in this research. The Macquarie Group or its associates, including MEL, may, is or has received fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case.

There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment.

The analyst(s) principally responsible for the preparation of this research receives compensation based on the Firm's overall revenues, including investment banking revenues. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. Disclosures applicable to research with respect to issuers, if any, mentioned herein, are available at www.macquarie.com.au/research/disclosures, through MEL at innercircle@macquarie.com.au or your Macquarie Financial Services representative.

Macquarie Equities Limited acted as Retail Broker to the issue of ITL Limited ordinary shares, announced 17 September 2003. The analyst and/or associated parties own or have other interests in securities issued by ITL.